MACCE
Pronunciation: MASS-ee
Also written as: MACCE — Major Adverse Cardiac and Cerebrovascular Events
Major adverse cardiac and cerebrovascular events, an expanded composite endpoint including stroke alongside traditional cardiac outcomes.
Full Definition
A composite clinical endpoint that extends beyond MACE (major adverse cardiac events) to include cerebrovascular events, particularly stroke. MACCE typically encompasses cardiovascular death, myocardial infarction, stroke, and target vessel revascularization, though specific definitions may vary between studies. This endpoint recognizes the interconnected nature of cardiovascular and cerebrovascular disease, particularly relevant in studies of interventions that may affect both vascular beds. The inclusion of stroke is especially important in trials involving devices or procedures that may carry embolic risk.
Usage
Usage note: Distinguish carefully from MACE; stroke inclusion must be explicitly stated in endpoint definitions.
In Context
- "The primary endpoint was MACCE at 12 months, with stroke adjudicated by an independent neurologist." — Clinical trial design
- "MACCE rates were significantly lower in the drug-eluting stent group compared to bare metal stents (8.3% vs. 12.7%, p=0.031)." — Results section